Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus Palonosetron

Vacirca, Jeffrey L.; Caruana, Dennis; Calcanes, George; Mosier, Michael; Boccia, Ralph V.; McBride, Ali

doi:10.2217/fon-2017-0720

Cited by 8 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, in the current retrospective study, the increase in unscheduled hydration requirements in patients receiving palonosetron compared with GERSC (each as part of a three-drug antiemetic regimen) would likely increase healthcare costs for patients who receive palonosetron as the 5-HT 3 RA in a three-or four-drug antiemetic regimen. Although this was a retrospective review of medical records at a single practice with multiple sites, similar results were reported in another retrospective study, in which 1.5 to two-times more patients required hydration events when receiving palonosetron than with GERSC (each as part of a three-drug antiemetic regimen) [25]. Further, in this analysis, for the HEC subgroup, approximately three-times more hydration events were required in patients treated with palonosetron than with GERSC.…”

Section: Discussionsupporting

confidence: 79%

“…Further, in this analysis, for the HEC subgroup, approximately three-times more hydration events were required in patients treated with palonosetron than with GERSC. Together, these findings suggest that GERSC may be preferred over palonosetron as the 5-HT 3 RA of choice in a three-drug antiemetic regimen, by reducing unscheduled hydration requirements [25]. A reduction in the number of hydration events required would be expected to decrease healthcare costs and improve patients' daily functioning and QoL.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Hydration Requirements in Patients Receiving Highly Emetogenic Chemotherapy

et al. 2018

View full text Add to dashboard Cite

Research Article Erickson, Nebughr, Mosier & Nibley medications, and needs for hydration with an iv. saline solution. Although guidelines from several organizations recommend combinations of drugs, known as antiemetics, to prevent CINV, there is still a need to improve CINV control. This study evaluated the need for hydration in patients with cancer who were receiving chemotherapy and an antiemetic drug combination including either palonosetron or granisetron extended-release subcutaneous (GERSC). Over half of patients who received palonosetron needed unscheduled hydration, compared with about a third of patients who received GERSC. Also, during each of the four cycles of chemotherapy given, the percentage of patients who needed hydration was higher with palonosetron than with GERSC. These results suggest that GERSC may be preferred over palonosetron in a three-drug antiemetic combination, by reducing the need for unscheduled hydration. This could reduce healthcare costs and improve patients' quality of life.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 93%

Hydration Requirements in Patients Receiving Highly Emetogenic Chemotherapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In innovaTV 204, the most common gastrointestinal TRAEs were nausea in 27 patients (27%; 17 with grade 1, 10 with grade 2) and decreased appetite in 11 patients (11%; 6 with grade 1, 5 with grade 2). Patients undergoing treatment with tisotumab vedotin may receive prophylactic antiemetics and other management strategies (e.g., hydration or steroids, per institutional guidelines; Coleman et al, 2021 ; Dielenseger et al, 2019 ; Miller & Kearney, 2004 ; Vacirca et al, 2018 ).…”

Section: Other Adverse Eventsmentioning

confidence: 99%

Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events

Arn

Halla

Gill

2023

JADPRO

View full text Add to dashboard Cite

Tisotumab vedotin-tftv, an antibody-drug conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, demonstrated clinically meaningful and durable responses with a manageable safety profile in the pivotal phase II innovaTV 204 clinical trial. Based on the proposed mechanism of action of tisotumab vedotin, experience from clinical trials, and the US prescribing information, certain adverse events (AEs) including ocular AEs, peripheral neuropathy, and bleeding have been identified as AEs of interest. This article highlights practical considerations and provides recommendations to support the management of selected AEs associated with tisotumab vedotin. Central to monitoring of patients on tisotumab vedotin is a comprehensive care team comprised of oncologists, advanced practice providers (including nurse practitioners, physician assistants, and pharmacists), and other specialists such as ophthalmologists. As ocular AEs may be less familiar to gynecologic oncology practitioners, adherence to the “Premedication and Required Eye Care” section outlined in the US prescribing information, as well as the incorporation of ophthalmologists into the oncology care team, can help provide timely and appropriate eye care for patients receiving tisotumab vedotin.

show abstract

“…Sustol® is administered on a weekly basis, via SC injection into the upper arm or abdomen that releases granisetron over more than 5 days. [184]. Sustol® is used for prevention of acute and delayed nausea and vomiting due to highly or moderately emetogenic anticancer chemotherapy or chemotherapeutic combination of anthracycline and cyclophosphamide [185].…”

Section: Marketed Non-plga Long Acting Parenteral Formulationsmentioning

confidence: 99%